Clinical Trial Update: Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing safety and efficacy of piperacillin/tazobactam versus cefepime in patients with hematologic neoplasms or lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Neoplasms
• Lymphoma

Drugs mentioned

• Cefepime (cefepime)
• Piperacillin/tazobactam (Piperacillin/tazobactam)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hematologic Neoplasms | Phase 3 | Status: COMPLETED